Cesentyx becomes a new psoriasis treatment option
The industry has attracted attention if Novartis’s Cosentyx(generic name: secukinumab) will deliver a new treatment option to severe psoriasis patients.
Last September, Novartis’s Cosentyx acquired approval as a severe plaque psoriasis for adults, who require phototherapy and whole body therapy(...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
